Medline (MDLN) FY2025 results: revenue $28.4 billion, up 11.5% on the year
Medline Inc. (MDLN) reported revenue of $28.4 billion for fiscal 2025, the year ended 31 December 2025, up 11.5% on the year before. Net income was $1.2 billion, down 0.3%, and diluted earnings per share $-0.01. The figures are the company's own, from the 10-K it filed with the SEC on 25 February 2026.
this yearthe year beforeHover a bar for its figure.
The year in brief
What management said about the year
Guidance figures: 2 new.
- Fourth quarter sales rose 14.8%: Fourth quarter net sales were $7,787 million, up from $6,784 million, with Organic Sales up 14.4%. The company said growth was primarily from increased volumes.
- Fourth quarter net income fell 37.7%: Net income was $180 million, down from $289 million. The company cited higher cost of goods sold from tariffs and higher operating costs, including headcount and IPO-related expenses, partly offset by higher sales.
- Fourth quarter Adjusted EBITDA roughly flat: Adjusted EBITDA was $805 million, down 0.6% from $810 million, with margin of 10.3% against 11.9%. Tariff costs and headcount investment offset higher net sales.
- Full year sales rose 11.5%: Full year net sales were $28.4 billion, up from $25.5 billion, with Organic Sales up 10.5%. Full year net income was $1.2 billion, down 3.6%.
- $2.4 billion of new customer signings: The company reported $2.4 billion of total new customer signings for 2025, measured as estimated annual contract value of new contracts, excluding renewals and extensions.
From this 10-K
Medline is a provider of medical-surgical ("med-surg") products and supply chain services, which the company describes as the largest on total net sales of med-surg products. It was founded in 1966 and sells to hospitals, surgery centers, physician offices and post-acute facilities. Through two segments it offers approximately 335,000 med-surg products, including surgical and procedural kits, gloves and protective apparel, urological and incontinence care, wound care, and consumable lab and diagnostics products. It employs over 45,000 people worldwide.
The four quarters: Q1 FY2025 · Q2 FY2025 · Q3 FY2025 · Q4 FY2025
Income statement (profit and loss)
| $ million | FY2025 | FY2024 | FY2023 | On the year | Last 8 years |
|---|---|---|---|---|---|
| Revenue | 28,432 | 25,507 | 23,231 | +11.5% | |
| Cost of revenue | 20,914 | 18,531 | 17,346 | +12.9% | |
| Gross profit | 7,518 | 6,976 | 5,885 | +7.8% | |
| Gross margin | 26.4% | 27.3% | 25.3% | ||
| Research and development | 80.0 | 67.0 | 60.0 | +19.4% | |
| Selling, general and administrative | 4,524 | 4,108 | 3,867 | +10.1% | |
| Operating income | 2,212 | 2,146 | 1,250 | +3.1% | |
| Operating margin | 7.8% | 8.4% | 5.4% | ||
| Interest expense | 945 | 1,144 | 1,213 | -17.4% | |
| Pre-tax income | 1,248 | 1,246 | 264 | +0.2% | |
| Income tax | 91.0 | 46.0 | 30.0 | +97.8% | |
| Effective tax rate | 7.3% | 3.7% | 11.4% | ||
| Net income | 1,159 | 1,163 | 234 | -0.3% | |
| Net margin | 4.1% | 4.6% | 1.0% | ||
| Diluted EPS | -$0.01 | n/a | n/a |
Read more
Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.Cash flow
| $ million | FY2025 | FY2024 | FY2023 | On the year | Last 8 years |
|---|---|---|---|---|---|
| Operating cash flow | 1,744 | 1,769 | 1,685 | -1.4% | |
| Capital expenditure | 447 | 354 | 275 | +26.3% | |
| Free cash flow | 1,297 | 1,415 | 1,410 | -8.3% | |
| Free cash flow margin | 4.6% | 5.5% | 6.1% | ||
| Cash from investing | -474 | -1,493 | -312 | ||
| Cash from financing | 399 | -1,613 | -191 | ||
| Depreciation and amortisation | 1,011 | 977 | 951 | +3.5% | |
| Share-based compensation | 76.0 | 61.0 | 78.0 | +24.6% | |
| Buybacks | 33.0 | 20.0 | 0.0 | +65.0% | |
| Diluted shares, weighted | 810m | n/a | n/a |
Balance sheet
| $ million | FY2025 | FY2024 | FY2023 | On the year | Last 8 years |
|---|---|---|---|---|---|
| Shareholders' equity | 10,737 | n/a | n/a | ||
| Non-controlling interest | 8,549 | n/a | n/a | ||
| Redeemable equity | 0.0 | 366 | 233 | ||
| Short-term borrowings | 1.0 | 2.0 | n/a | -50.0% | |
| Debt | 12,560 | 16,492 | n/a | -23.8% | |
| Operating lease liabilities | 386 | 329 | n/a | +17.3% | |
| Other liabilities | 6,251 | n/a | n/a | ||
| Total liabilities and equity | 38,484 | 35,978 | n/a | +7.0% | |
| Fixed assets | 4,778 | 4,595 | n/a | +4.0% | |
| Goodwill | 8,079 | 8,065 | 7,532 | +0.2% | |
| Intangible assets | 13,893 | 14,559 | n/a | -4.6% | |
| Investments | 0.0 | n/a | n/a | ||
| Cash and equivalents | 1,939 | 199 | 1,585 | +874.4% | |
| Receivables | 3,533 | 3,219 | n/a | +9.8% | |
| Inventory | 4,769 | 4,456 | n/a | +7.0% | |
| Other assets | 1,493 | 885 | n/a | +68.7% | |
| Total assets | 38,484 | 35,978 | n/a | +7.0% |
10-K for the year ended 31 December 2025, filed 25 February 2026: the filing.